17,261 trials
Retinitis Pigmentosa (RP)
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability — 25; 21; 1 Participants
Dementia of Alzheimer's Type
Primary: Number of Participants Who Reached the Maximum Allowed Dose (MAD) in Their Respective Cohort — 2; 0; 1; 6 Participants
Stage II Breast Cancer · Stage IIIA Breast Cancer · Stage IIIB Breast Cancer
Primary: Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by…
Superficial Basal Cell Carcinoma
Primary: Number of Participants With Complete Response — 9; 5; 7; 9 Participants
HIV Infections · Lipodystrophy
Primary: Fasting Serum Triglycerides — 237; 341 mg/dL — p=0.84
Breast Cancer
Primary: Change in Ki-67 Levels From Baseline (Pre) to Day 28 (Post) Biopsy Samples — -1.3632; -1.6237 log-transformed Ki67% — p=0.6202
Complicated Intra-Abdominal Infections, cIAIs
Primary: Plasma Concentration of Aztreonam (ATM): Sparse Sampling at Day 1, 0 hr — 0.1 microgram per milliliter (mcg/mL)
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
NSCLC
Primary: Disease Control (Defined as Complete or Partial Response, or Disease Stabilisation Lasting at Least 12 Weeks) — 7; 6; 4; 5 Participants
Renal Transplant Osteodystrophy
Primary: Bone Mineral Density of Spine at 6 Months — 0.98; 0.97 gm/cm^2
Recurrent Merkel Cell Carcinoma · Stage III Merkel Cell Carcinoma AJCC v7 · Stage IIIA Merkel Cell Carcinoma AJCC v7
Primary: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation…
Non-arteritic Ischemic Optic Neuropathy · Optic Nerve Injuries
Primary: Mean Increase From Baseline in ETDRS Letters Read at 26 Weeks and Off-drug Follow-up Visit — 15; 7; 9; 6 EDTRS Letters
Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma
Primary: Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 3 Participants
Colorectal Carcinoma
Primary: Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization — 46.4; 47.4 percentage of participants
Acne Vulgaris
Primary: Total Lesion Count (Inflammatory and Non-inflammatory) — 23.57; 32.90 Lesions — p=<.001